Cornell Preprint: Interactomics Screen Reveals New Kratom Alkaloid Biosynthetic Pathways

Why it matters

A new Cornell University preprint reports the discovery of previously unknown alkaloid biosynthetic pathways in kratom using a yeast-based protein interaction screen. The work identifies six novel enzymes and two new alkaloids, advancing the basic science that could eventually enable pharmaceutical synthesis of kratom-derived compounds.

The big picture

Understanding how kratom produces its pharmacologically active alkaloids — including mitragynine — is a prerequisite for developing synthetic or semi-synthetic derivatives with precisely tuned therapeutic profiles. Cornell's earlier work (April 2026) completed the full biosynthetic pathway in yeast; this follow-on study digs deeper into the plant's enzymatic machinery using an interactomics approach, finding even more complexity in the pathway.

Key findings

• Researchers used a large-scale yeast-based protein-protein interaction (PPI) screen focused on a key kratom enzyme (strictosidine beta-D-glucosidase, SGD)
• Six novel medium-chain dehydrogenase/reductase (MDR) enzymes were identified as high-confidence SGD interaction partners
• All six MsMDRs produce a new monoterpene indole alkaloid (MIA) the team named 'charlamine'
• One MsMDR also converts another intermediate into a second new alkaloid, 'vallesiachotaminol'
• A biosynthetic gene cluster containing a downstream esterase enzyme was also discovered, indicating the pathway is more complex than previously known
• Funded by NIH (R01AT012633) and the National Science Foundation

What they say

The Cornell research team, led by Sijin Li, states the findings 'demonstrate the utility of interactomics-driven plant pathway discovery,' presenting a scalable method for mapping hidden biosynthetic routes in pharmacologically important plants.

Bottom line

**Cornell researchers have discovered two entirely new kratom alkaloids and six previously unknown enzymes in the plant's biosynthetic pathway — advancing the foundational science needed to engineer safer, pharmaceutical-grade kratom-derived compounds.**